In Section C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment until finally sickness progression or the contributors are not able to tolerate the study drugs. Celastrol was determined being a Myb inhibitor that suppressed C/EBPβ exercise and https://clinicaleffectivenessofab80134.theisblog.com/32133545/the-basic-principles-of-abbv-744-in-acute-myeloid-leukemia-aml